• Longer time from diagnosis to definitive surgery (TTDS) is associated with increased melanoma-specific mortality; in this study, Black patients have longer TTDS for melanoma after controlling for sociodemographic factors, and these differences persist for each insurance, Stage I-III melanoma, and for time to immunotherapy.
INTRODUCTION
An estimated 2.3% of Americans are diagnosed with cutaneous melanoma annually, and the national incidence of cutaneous melanoma has continued to rise over the past decade. 1 It has been shown that dermatology visits reduce adverse events, mortality, and unnecessary hospitalizations for melanoma patients. 2, 3 However, substantial disparities in access to and utilization of dermatologic care for melanoma patients have been demonstrated for a myriad of clinical and sociodemographic factors including age, sex, rurality, provider supply, distance to dermatologic care, and poverty rate. 4, 5 Specifically, race and insurance status are associated with differences in disease-specific mortality for melanoma patients. [6] [7] [8] Black patients present with later stage melanoma, and later stage melanoma at diagnosis and increased time to treatment for stage I melanoma have each independently been associated with increased melanoma-specific mortality. 6, [8] [9] [10] Despite this, the association between race and time from diagnosis to definitive surgery (TTDS) is unknown.
As such, our primary goal was to investigate differences in TTDS between Black and non-Hispanic white (NHW) melanoma patients. Our secondary goals were to determine differences in TTDS between Black and NHW patients by melanoma stage and insurance type, and to examine racial differences in stage at presentation, distance from the hospital, and time to medical treatment (immunotherapy and chemotherapy).
METHODS
Patients with cutaneous melanoma were identified using the National Cancer Database Table 4 ).
DISCUSSION
In this study, Black patients had greater TTDS for stages I-III melanoma and greater time to immunotherapy compared to NHW patients, and the racial differences in TTDS persisted within each insurance type. There were no racial differences in TTDS for Stage IV melanoma or time to chemotherapy. Additionally, compared to NHW patients, Black patients had over twice the odds of having TTDS between 41-60 days, over three times the odds of having TTDS between 61-90 days, and over five times the odds of having TTDS over 90 days.
These findings add to the literature by demonstrating increased TTDS for Black patients with melanoma after controlling for sex, age, income, and insurance type. Our data suggest that increased TTDS in Black patients with melanoma may be an independent explanatory factor for racial differences in melanoma survival alongside factors such as later stage at presentation, biological differences in melanoma characteristics, and differences in healthcare utilization. 6, 9, 12 Multiple unfavorable socioeconomic factors may exacerbate overall health status more than the additive effects of each of the individual factors. 13 Racial differences in TTDS persisted within each insurance group, implying that insurance status does not fully account for racial TTDS disparities. We found that Black patients also had increased TTDS despite living closer to hospitals, suggesting physical distance from the hospital is not as much of a contributor to TTDS for melanoma as for other cancers (e.g. colorectal). 14 A recent study of three high-risk surgical procedures showed that Black patients lived closer to high-quality hospitals but were 25-58% more likely to receive surgery at low-quality hospitals than NHW patients; it is possible that a similar phenomenon exists in TTDS for melanoma. 15 The quality and availability of melanoma treatment may thus be significantly different between racial groups for reasons other than travel burden . 15 Efforts to geographically centralize care for melanoma should consider that disparities may be driven by other extrinsic and intrinsic patient-level factors. Creation of a model delineating interactions between the myriad components underlying worse outcomes for Black melanoma patients, including race and insurance status, is critical in identifying targeted avenues for intervention.
Difference in disease characteristics by race may also impact time to treatment for melanoma. Black patients more often present with acral lentiginous melanoma (ALM) on the lower extremities and have increased Breslow depth and stage at diagnosis for other melanoma subtypes, which portends worse prognosis. 16 Several controversies exist in the treatment of ALM that are not present in the treatment of other melanoma subtypes (such as superficial spreading melanoma), including appropriate excision margins, difficulty of primary closure, efficacy of secondary intention healing, and the use of flaps and grafts. [17] [18] [19] [20] Furthermore, ALM may have less susceptibility to immunotherapy due to poor immunogenicity and infrequent BRAF mutation. 18 These controversies and challenges in treatment of ALM may necessitate further planning and coordination, and thus increase TTDS and time to treatment for melanoma in Black patients; ultimately, this may further exacerbate disparities in outcomes.
For a variety of cancers, including breast and colorectal, stage at presentation plays a stronger independent role in survival than race. 21, 22 When stratified by stage, Black patients had increased TTDS for stages I-III melanoma, but not stage IV melanoma. Racial disparities in time to treatment may thus be less prominent for melanoma that has metastasized. Immunotherapy and targeted therapy are increasingly becoming the standard of care for patients with metastatic melanoma. 23 It has been shown that Black patients are less likely to receive immunotherapy for metastatic melanoma and various other cancers after controlling for other sociodemographic factors. 23, 24 Our research also adds to the growing knowledge base regarding disparities in immunotherapy by showing that Black patients receive immunotherapy an average of 21.5 days later than NHW patients. As utilization of immunotherapy for melanoma continues to grow, it is important to better understand and address these underlying racial disparities.
Strengths of this study include use of one of the largest cancer registries in the world with rigorous quality assurance measures, variability in geography and hospital type, and availability of several nuances of treatment and staging that are not present in state-based registries. One limitation is that patients were matched by broader age group and stage categories rather than smaller age intervals and stage subcategories. Additionally, limited information was available to further characterize the heterogeneity of chemotherapy and immunotherapy. Finally, in 2005, 48.4% of all melanomas in the US were included in NCDB; the NCDB may not be generalizable to the entire US population given that it is a hospital-based registry and there may be disproportionate representation of certain groups.
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CONCLUSION
This study investigated racial differences in time to treatment for melanoma using a large hospital-based administrative healthcare database. Black patients had greater TTDS for melanoma than NHW patients after controlling for other sociodemographic factors, and racial differences in TTDS persisted after stratifying by insurance type and melanoma stage.
Ultimately, it is important to better understand the various components underlying worse outcomes for Black melanoma patients. Targeted approaches to improve TTDS for Black melanoma patients are integral in reducing racial disparities in melanoma outcomes. Abbreviations: TTDS, time to definitive surgical treatment; NHW, non-Hispanic white; SD, standard deviation. Abbreviations: TTDS, time to definitive surgical treatment; NHW, non-Hispanic white; SD, standard deviation. Abbreviations: CI, confidence interval.
TABLES
